vs
Side-by-side financial comparison of Organon & Co. (OGN) and Optimum Communications, Inc. (OPTU). Click either name above to swap in a different company.
Optimum Communications, Inc. is the larger business by last-quarter revenue ($2.2B vs $1.5B, roughly 1.5× Organon & Co.). Organon & Co. runs the higher net margin — 10.0% vs -3.3%, a 13.3% gap on every dollar of revenue. On growth, Optimum Communications, Inc. posted the faster year-over-year revenue change (-2.3% vs -3.5%). Over the past eight quarters, Optimum Communications, Inc.'s revenue compounded faster (-1.5% CAGR vs -4.7%).
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
Optimum Communications, Inc. is an American telecommunications provider owned by Franco-Israeli businessman Patrick Drahi. The company primarily provides digital cable television and broadband services in the New York metropolitan area as well as in several Midwestern and Southern U.S. states. With approximately 4.9 million residential and business customers in 21 U.S. states as of 2017 it is the fourth-largest telecommunications company in the United States. Optimum is based at One Court Squ...
OGN vs OPTU — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.2B |
| Net Profit | $146.0M | $-71.2M |
| Gross Margin | 53.6% | 69.5% |
| Operating Margin | — | 18.2% |
| Net Margin | 10.0% | -3.3% |
| Revenue YoY | -3.5% | -2.3% |
| Net Profit YoY | 67.8% | -31.6% |
| EPS (diluted) | $0.55 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $2.2B | ||
| Q3 25 | $1.6B | $2.1B | ||
| Q2 25 | $1.6B | $2.1B | ||
| Q1 25 | $1.5B | $2.2B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.6B | $2.2B |
| Q1 26 | $146.0M | — | ||
| Q4 25 | $-205.0M | $-71.2M | ||
| Q3 25 | $160.0M | $-1.6B | ||
| Q2 25 | $145.0M | $-96.3M | ||
| Q1 25 | $87.0M | $-75.7M | ||
| Q4 24 | $109.0M | $-54.1M | ||
| Q3 24 | $359.0M | $-43.0M | ||
| Q2 24 | $195.0M | $15.4M |
| Q1 26 | 53.6% | — | ||
| Q4 25 | 49.2% | 69.5% | ||
| Q3 25 | 53.5% | 69.7% | ||
| Q2 25 | 54.8% | 69.1% | ||
| Q1 25 | 55.6% | 68.8% | ||
| Q4 24 | 56.3% | 67.7% | ||
| Q3 24 | 58.3% | 68.1% | ||
| Q2 24 | 58.4% | 67.9% |
| Q1 26 | — | — | ||
| Q4 25 | -9.8% | 18.2% | ||
| Q3 25 | 15.2% | -55.3% | ||
| Q2 25 | 14.4% | 14.5% | ||
| Q1 25 | 6.7% | 16.0% | ||
| Q4 24 | 8.1% | 15.2% | ||
| Q3 24 | 13.1% | 20.0% | ||
| Q2 24 | 14.6% | 22.4% |
| Q1 26 | 10.0% | — | ||
| Q4 25 | -13.6% | -3.3% | ||
| Q3 25 | 10.0% | -77.1% | ||
| Q2 25 | 9.1% | -4.5% | ||
| Q1 25 | 5.8% | -3.5% | ||
| Q4 24 | 6.8% | -2.4% | ||
| Q3 24 | 22.7% | -1.9% | ||
| Q2 24 | 12.1% | 0.7% |
| Q1 26 | $0.55 | — | ||
| Q4 25 | $-0.78 | $-0.16 | ||
| Q3 25 | $0.61 | $-3.47 | ||
| Q2 25 | $0.56 | $-0.21 | ||
| Q1 25 | $0.33 | $-0.16 | ||
| Q4 24 | $0.42 | $-0.11 | ||
| Q3 24 | $1.38 | $-0.09 | ||
| Q2 24 | $0.75 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.0B |
| Total DebtLower is stronger | — | $26.2B |
| Stockholders' EquityBook value | — | $-2.3B |
| Total Assets | — | $30.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $574.0M | $1.0B | ||
| Q3 25 | $672.0M | $938.8M | ||
| Q2 25 | $599.0M | $247.3M | ||
| Q1 25 | $547.0M | $279.1M | ||
| Q4 24 | $675.0M | $256.5M | ||
| Q3 24 | $763.0M | $250.0M | ||
| Q2 24 | $704.0M | $362.1M |
| Q1 26 | — | — | ||
| Q4 25 | $8.6B | $26.2B | ||
| Q3 25 | $8.8B | $26.2B | ||
| Q2 25 | $8.9B | $25.3B | ||
| Q1 25 | $9.0B | $25.3B | ||
| Q4 24 | $8.9B | $25.1B | ||
| Q3 24 | $8.7B | $25.1B | ||
| Q2 24 | $8.7B | $25.2B |
| Q1 26 | — | — | ||
| Q4 25 | $752.0M | $-2.3B | ||
| Q3 25 | $906.0M | $-2.2B | ||
| Q2 25 | $733.0M | $-624.1M | ||
| Q1 25 | $542.0M | $-543.0M | ||
| Q4 24 | $472.0M | $-469.2M | ||
| Q3 24 | $493.0M | $-427.1M | ||
| Q2 24 | $144.0M | $-399.1M |
| Q1 26 | — | — | ||
| Q4 25 | $12.9B | $30.7B | ||
| Q3 25 | $13.6B | $30.7B | ||
| Q2 25 | $13.5B | $31.6B | ||
| Q1 25 | $13.2B | $31.7B | ||
| Q4 24 | $13.1B | $31.7B | ||
| Q3 24 | $12.8B | $31.8B | ||
| Q2 24 | $12.2B | $32.0B |
| Q1 26 | — | — | ||
| Q4 25 | 11.49× | — | ||
| Q3 25 | 9.74× | — | ||
| Q2 25 | 12.14× | — | ||
| Q1 25 | 16.52× | — | ||
| Q4 24 | 18.81× | — | ||
| Q3 24 | 17.75× | — | ||
| Q2 24 | 60.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $481.6M |
| Free Cash FlowOCF − Capex | — | $199.4M |
| FCF MarginFCF / Revenue | — | 9.1% |
| Capex IntensityCapex / Revenue | — | 12.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-118.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $141.0M | $481.6M | ||
| Q3 25 | $264.0M | $147.4M | ||
| Q2 25 | $220.0M | $412.0M | ||
| Q1 25 | $75.0M | $187.5M | ||
| Q4 24 | $390.0M | $439.9M | ||
| Q3 24 | $141.0M | $436.0M | ||
| Q2 24 | $332.0M | $306.8M |
| Q1 26 | — | — | ||
| Q4 25 | $96.0M | $199.4M | ||
| Q3 25 | $218.0M | $-178.1M | ||
| Q2 25 | $181.0M | $28.4M | ||
| Q1 25 | $43.0M | $-168.6M | ||
| Q4 24 | $335.0M | $49.9M | ||
| Q3 24 | $99.0M | $76.9M | ||
| Q2 24 | $300.0M | $-40.9M |
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 9.1% | ||
| Q3 25 | 13.6% | -8.4% | ||
| Q2 25 | 11.4% | 1.3% | ||
| Q1 25 | 2.8% | -7.8% | ||
| Q4 24 | 21.0% | 2.2% | ||
| Q3 24 | 6.3% | 3.5% | ||
| Q2 24 | 18.7% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 12.9% | ||
| Q3 25 | 2.9% | 15.4% | ||
| Q2 25 | 2.4% | 17.9% | ||
| Q1 25 | 2.1% | 16.5% | ||
| Q4 24 | 3.5% | 17.5% | ||
| Q3 24 | 2.7% | 16.1% | ||
| Q2 24 | 2.0% | 15.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 3.58× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 1.70× | 19.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
OPTU
| Total Residential Revenue | $1.6B | 74% |
| Business Servicesand Wholesale | $401.8M | 18% |
| Telephony | $60.8M | 3% |
| Other | $57.9M | 3% |
| Franchise | $50.0M | 2% |
